Impella use in acute myocardial infarction complicated by cardiogenic shock and cardiac arrest: Analysis of 10 years registry data

Resuscitation. 2019 Jul:140:178-184. doi: 10.1016/j.resuscitation.2019.04.022. Epub 2019 Apr 19.

Abstract

Aims: To assess characteristics and outcome of patients treated with Impella for acute myocardial infarction (AMI) complicated by severe cardiogenic shock (CS) or cardiac arrest (CA).

Methods and results: From 2008 through 2017, 92 patients with AMI complicated by CS were treated with Impella. Survival varied according to clinical presentation. Patients in cardiogenic shock without CA had a 75% 30-day survival. Patients with CA and return of spontaneous circulation (ROSC) had a 43% survival and those with CA and ongoing cardio-pulmonary resuscitation (CPR) had a 6% 30-day survival. Age, pre-existing hypertension, coronary disease, ventilatory support and use of adrenergic agents were associated with worse prognosis. Complications were predominantly access site related.

Conclusions: In this registry of patients with AMICS treated with Impella, hypertension and older age were found to be negatively predictive for survival. Patients without CA had the highest 30-day survival. In patients with ROSC, survival was strongly related to age and comorbidity. Patients with ongoing CPR had very high mortality.

Keywords: Acute myocardial infarction; Cardiogenic shock; Left ventricular assist device; Mechanical circulatory support.

MeSH terms

  • Aged
  • Cardiopulmonary Resuscitation / adverse effects
  • Cardiopulmonary Resuscitation / statistics & numerical data
  • Female
  • Heart Arrest / etiology
  • Heart Arrest / mortality
  • Heart Arrest / therapy*
  • Heart-Assist Devices*
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / complications
  • Myocardial Infarction / mortality
  • Myocardial Infarction / therapy*
  • Proportional Hazards Models
  • Registries
  • Retrospective Studies
  • Shock, Cardiogenic / etiology
  • Shock, Cardiogenic / mortality
  • Shock, Cardiogenic / therapy*